Reported lives saved with the help of EVZIO*

Based on voluntary reports from recipients of donated product; is not based on clinical outcomes studies.

In an opioid emergency…

SECONDS
COUNT

Reach for Voice Guidance

EVZIO is the first and only intelligent take-home 2 mg naloxone auto-injection system with voice and visual guidance—designed to help caregivers take fast, confident action administering naloxone in an opioid emergency.1

Answers to 2 mg FAQs
  • Trainer

    Educate your patients on what to do in an opioid emergency.

    Include the Trainer for EVZIO in the discussion.

    Request One Today

  • EVZIO Direct

    Mail-Order Pharmacy Program

    To learn more and download the EVZIO Direct enrollment form

    Click Here

  • $0 Copay for commercially insured patients

    Your patients may be able to save by lowering out-of-pocket costs on their EVZIO prescription. Terms and Conditions may apply.

    See How to Save

FREQUENTLY ASKED QUESTIONS

Why was the dose of naloxone in EVZIO increased from 0.4 mg to 2 mg?

EVZIO is the first and only 2 mg take-home naloxone auto-injection system for use in opioid emergencies, including those with synthetic opioids like fentanyl, long-acting opioids, and partial agonists or mixed agonist/antagonists. These may require higher or repeat doses of naloxone.2-4

Is the 0.4 mg dose not effective?

EVZIO 0.4 mg remains a safe and effective, FDA-approved option for treatment of an opioid emergency.

Can my patients still use EVZIO 0.4 mg?

Yes—EVZIO 0.4 mg remains an safe and effective, FDA-approved option for treatment of an opioid emergency.

Can I still prescribe EVZIO 0.4 mg?

EVZIO 2 mg is now available. You should write all prescriptions for EVZIO 2 mg to ensure that the patient receives EVZIO 2 mg quickly. EVZIO 0.4 mg will no longer be manufactured.

Where do I go for more information on EVZIO 2 mg?

For more information on EVZIO 2 mg, call 1-855-77-EVZIO (1-855-773-8946).

STAY VIGILANT: COPRESCRIBE EVZIO AS AN IMPORTANT PART OF YOUR PATIENT’S OPIOID EMERGENCY PLAN

  • Government agencies and medical organizations have recognized the need for improved access to naloxone in the community—some also recommend coprescribing naloxone
References: 1. Data on file. Richmond, VA; kaleo, Inc. 2. Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit. HHS Publication No. (SMA) 16-4742. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2016. 3. CDC Health Advisory. Increases in fentanyl drug confiscation and fentanyl-related overdose fatalities. October 26, 2015. http://emergency.cdc.gov/han/han00384.asp. Accessed November 21, 2016. 4. EVZIO (naloxone hydrochloride injection) Auto-injector [prescribing information]. Richmond, VA: kaleo, Inc; 2016.
INDICATION

EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.

Seek emergency medical assistance immediately after use. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.

The following warnings and precautions should be taken when administering EVZIO:

  • Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeated doses of naloxone using a new EVZIO, as necessary, while awaiting emergency medical assistance.
  • Risk of Limited Efficacy With Partial Agonists or Mixed Agonists/ Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/ antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
  • Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
  • Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.


The following adverse reactions were most commonly observed in EVZIO clinical studies: dizziness and injection site erythema.

Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated signs and symptoms of opioid withdrawal including: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In the neonate, opioid withdrawal signs and symptoms also included: convulsions, excessive crying, and hyperactive reflexes.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information.

To opt out of receiving communications regarding EVZIO, click here.

This website is intended for US audiences only.

  • ©2017 kaleo, Inc.
  • All rights reserved.
  • PP-EVZ-US-1299
  • April 2017
IMPORTANT SAFETY INFORMATION

INDICATION

EVZIO is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems and severe sleepiness or not being able to respond.

INDICATION

EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.

Seek emergency medical assistance immediately after use. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.

The following warnings and precautions should be taken when administering EVZIO:

  • Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeated doses of naloxone using a new EVZIO, as necessary, while awaiting emergency medical assistance.
  • Risk of Limited Efficacy With Partial Agonists or Mixed Agonists/ Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/ antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
  • Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
  • Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.


The following adverse reactions were most commonly observed in EVZIO clinical studies: dizziness and injection site erythema.

Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated signs and symptoms of opioid withdrawal including: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In the neonate, opioid withdrawal signs and symptoms also included: convulsions, excessive crying, and hyperactive reflexes.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information.